Cipher Pharmaceuticals (TSX:CPH) reveals it has acquired global rights and operations for a lice and scabies treatment for US$89.5 millionThe company acquired the products from ParaPro, which are called Natroba and its authorized generic SpinosadNo generic alternatives are apparently available for these productsShares of Cipher Pharmaceuticals are up 26.38 per cent to C$10.97 as of 11:10 am ETCipher Pharmaceuticals (TSX:CPH) reveals it has acquired global rights and operations for a lice and scabies treatment for US$89.5 million. The company said in a release that it had acquired the products …